[Tolerance of high dosage @entity2049 monotherapy in treatment of XXXX ].

@entity1 @entity2049 @entity302 @entity2050
We examined whether high dose @entity2049 ( @entity2050 ) monotherapy ( @entity2050 serum levels > 9 mg/l) is well tolerated. Forty-one @entity1 with localisation-related @entity302 were enrolled. They received high dose monotherapy either from the time of recruitment (30/41), or their @entity2050 treatment was pushed into the high dose range (11/41) during the observation period (mean 145 days). @entity2050 and @entity2050 metabolite serum levels, full blood counts, liver function tests, electrolytes were measured in addition to clinical assessments. The mean daily @entity2050 dose was 1515 mg (median 1500, range 600-3600 mg). Mean @entity2050 serum level was 11.1 mg/l (median 11.1, range 5.3-16.4 mg/l). Eleven of 41 @entity1 (26.8%) reported side effects (mean serum level 11.4, median 11.6, range 8.7-13.7 mg/l), but side effects were intolerable in only five @entity1 so that the @entity2050 dose had to be reduced (mean @entity2050 serum level 11.4, median 11.6, range 8.7-13.7 mg/l). The total daily @entity2050 dose but not @entity2050 or @entity2050 metabolite levels were correlated with side effects. No treatment changes had to be undertaken because of abnormal laboratory parameters. High dose @entity2050 anticonvulsant monotherapy is well tolerated.
